Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet Commentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases   Commentary on Twitter NEW—Chinese #COVID19 vaccine […]

The post Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial appeared first on Links Medicus.